Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NYSE:BHVN NASDAQ:CMPX NASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$66.15+1.3%$63.56$52.50▼$77.00$1.43B0.57314,151 shs191,074 shsBHVNBiohaven$14.82+2.3%$16.26$13.75▼$55.70$1.51B0.911.30 million shs933,333 shsCMPXCompass Therapeutics$2.84+3.5%$2.27$0.87▼$4.08$393.41M1.48971,125 shs732,658 shsJANXJanux Therapeutics$25.40-0.4%$24.90$22.48▼$71.71$1.50B2.86867,100 shs346,846 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.37%+0.14%+3.37%+0.29%+6.47%BHVNBiohaven+3.96%-2.17%-15.38%-15.46%-58.98%CMPXCompass Therapeutics+3.40%+4.58%+6.61%+66.06%+216.40%JANXJanux Therapeutics+4.25%+5.94%-1.73%-5.14%-38.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.4065 of 5 stars2.51.00.03.30.63.31.3BHVNBiohaven3.1739 of 5 stars4.51.00.00.01.82.50.6CMPXCompass Therapeutics2.4536 of 5 stars3.62.00.00.00.05.00.0JANXJanux Therapeutics1.5412 of 5 stars3.51.00.00.00.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$78.8819.25% UpsideBHVNBiohaven 3.07Buy$58.46294.61% UpsideCMPXCompass Therapeutics 3.10Buy$12.67346.80% UpsideJANXJanux Therapeutics 3.09Buy$95.25275.06% UpsideCurrent Analyst Ratings BreakdownLatest CMPX, JANX, BHVN, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$84.007/1/2025CMPXCompass TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform$9.006/18/2025BHVNBiohavenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.005/19/2025BHVNBiohavenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.004/28/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.004/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/24/2025BHVNBiohavenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.33$7.73 per share8.56$19.11 per share3.46BHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/ACMPXCompass Therapeutics$850K461.20N/AN/A$0.91 per share3.12JANXJanux Therapeutics$10.59M141.90N/AN/A$19.49 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.71N/A-3.12%21.35%7.52%8/5/2025 (Estimated)BHVNBiohaven-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)Latest CMPX, JANX, BHVN, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025JANXJanux Therapeutics-$0.50N/AN/AN/A$0.30 millionN/A8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98BHVNBiohavenN/A2.332.33CMPXCompass TherapeuticsN/A8.338.33JANXJanux TherapeuticsN/A58.4758.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%BHVNBiohaven88.78%CMPXCompass Therapeutics68.43%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%BHVNBiohaven16.00%CMPXCompass Therapeutics29.80%JANXJanux Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableBHVNBiohaven239102.11 million85.78 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableJANXJanux Therapeutics3059.17 million54.38 millionOptionableCMPX, JANX, BHVN, and ANIP HeadlinesRecent News About These CompaniesJanux Therapeutics Inc Ordinary Shares JANX - MorningstarJune 27, 2025 | morningstar.comMJonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price TargetJune 24, 2025 | msn.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by BrokeragesJune 21, 2025 | marketbeat.comJanux Therapeutics Becomes Oversold (JANX)June 20, 2025 | nasdaq.comSG Americas Securities LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)June 20, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 3.6% - Should You Sell?June 16, 2025 | marketbeat.comResearch Analysts Offer Predictions for JANX FY2026 EarningsJune 10, 2025 | marketbeat.comWhy Janux Therapeutics, Inc.’s (JANX) Stock Is Down 7.22%May 15, 2025 | aaii.comAJanux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development OfficerMay 15, 2025 | finance.yahoo.comJanux Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comJanux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside PotentialMay 6, 2025 | finance.yahoo.comJanux Therapeutics begins phase 1b trial for prostate cancer therapyMay 6, 2025 | investing.comJanux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program UpdatesMay 5, 2025 | finance.yahoo.comJanux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside PotentialMay 5, 2025 | insidermonkey.comIs Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?May 5, 2025 | insidermonkey.comJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $106,755.99 in StockMay 3, 2025 | insidertrades.comWhy Janux Therapeutics, Inc.’s (JANX) Stock Is Down 5.83%April 26, 2025 | aaii.comAJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Andrew Hollman Meyer Sells 3,334 SharesApril 24, 2025 | insidertrades.comJanux Therapeutics: What's My Inflection Point?April 7, 2025 | seekingalpha.comJanux Therapeutics: What's My Inflection Point?April 7, 2025 | seekingalpha.comJanux Therapeutics: Buying For The Promising Pipeline, Holding For The BuyoutApril 5, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPX, JANX, BHVN, and ANIP Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$66.14 +0.84 (+1.28%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Biohaven NYSE:BHVN$14.82 +0.34 (+2.31%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Compass Therapeutics NASDAQ:CMPX$2.84 +0.10 (+3.47%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Janux Therapeutics NASDAQ:JANX$25.40 -0.09 (-0.37%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Boeing's Rebound Is Well Underway—But Is It Too Late? Why Microsoft Keeps Showing Up in Congressional Portfolios Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
